These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 8177988)

  • 1. Sample size determination for an exponential survival model with an unrestricted covariate.
    Zhen B; Murphy JR
    Stat Med; 1994 Feb; 13(4):391-7. PubMed ID: 8177988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sample size determination for comparing several survival curves with unequal allocations.
    Halabi S; Singh B
    Stat Med; 2004 Jun; 23(11):1793-815. PubMed ID: 15160409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formula predicting survival in patients with invasive cutaneous malignant melanoma.
    Chung SJ
    Int J Biomed Comput; 1991; 28(3):151-9. PubMed ID: 1937943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monte Carlo simulation of the power of a test for the exponential distribution of survival times.
    Holland B
    Comput Methods Programs Biomed; 1989 Aug; 29(4):245-50. PubMed ID: 2791525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Simulation Based Evaluation of the Asymptotic Power Formulae for Cox Models in Small Sample Cases.
    Kocak M; Onar-Thomas A
    Am Stat; 2012; 66(3):173-179. PubMed ID: 24115780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proportional hazards under Conway-Maxwell-Poisson cure rate model and associated inference.
    Balakrishnan N; Barui S; Milienos FS
    Stat Methods Med Res; 2017 Oct; 26(5):2055-2077. PubMed ID: 28523958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gut microbiome and immunotherapy response.
    Burki TK
    Lancet Oncol; 2017 Dec; 18(12):e717. PubMed ID: 29129446
    [No Abstract]   [Full Text] [Related]  

  • 8. Enhanced survival in patients with multiple primary melanoma.
    Doubrovsky A; Menzies SW
    Arch Dermatol; 2003 Aug; 139(8):1013-8. PubMed ID: 12925389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival from melanoma of the skin in England and Wales up to 2001.
    Ottensmeier CH; Gore M
    Br J Cancer; 2008 Sep; 99 Suppl 1(Suppl 1):S50-2. PubMed ID: 18813259
    [No Abstract]   [Full Text] [Related]  

  • 10. On the Conditional Power in Survival Time Analysis Considering Cure Fractions.
    Kuehnapfel A; Schwarzenberger F; Scholz M
    Int J Biostat; 2017 Mar; 13(1):. PubMed ID: 28328527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subgroup detection and sample size calculation with proportional hazards regression for survival data.
    Kang S; Lu W; Song R
    Stat Med; 2017 Dec; 36(29):4646-4659. PubMed ID: 28791726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Power and sample size for dose-finding studies with survival endpoints under model uncertainty.
    Deng Q; Bai X; Liu D; Roy D; Ying Z; Lin DY
    Biometrics; 2019 Mar; 75(1):308-314. PubMed ID: 30203467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simulating survival data with predefined censoring rates for proportional hazards models.
    Wan F
    Stat Med; 2017 Feb; 36(5):838-854. PubMed ID: 27873333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flexible estimation of survival curves conditional on non-linear and time-dependent predictor effects.
    Wynant W; Abrahamowicz M
    Stat Med; 2016 Feb; 35(4):553-65. PubMed ID: 26542758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination immunotherapy breakthrough for melanoma.
    Brower V
    Lancet Oncol; 2015 Jul; 16(7):e318. PubMed ID: 26062775
    [No Abstract]   [Full Text] [Related]  

  • 16. Nail apparatus melanoma: A comparative, clinicoprognostic study of the initial clinical and morphological characteristics of 49 patients.
    Lee WJ; Lee JH; Won CH; Chang SE; Choi JH; Moon KC; Lee MW
    J Am Acad Dermatol; 2015 Aug; 73(2):213-20. PubMed ID: 26028523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimating the average treatment effect on survival based on observational data and using partly conditional modeling.
    Gong Q; Schaubel DE
    Biometrics; 2017 Mar; 73(1):134-144. PubMed ID: 27192660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel sample size formula for the weighted log-rank test under the proportional hazards cure model.
    Xiong X; Wu J
    Pharm Stat; 2017 Jan; 16(1):87-94. PubMed ID: 27860138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using benchmarks based on historical survival rates for screening new therapies for stage IV melanoma patients.
    Gimotty PA; Guerry D; Flaherty K
    J Clin Oncol; 2008 Feb; 26(4):517-8. PubMed ID: 18235111
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinically amelanotic or hypomelanotic melanoma: Anatomic distribution, risk factors, and survival.
    Wee E; Wolfe R; Mclean C; Kelly JW; Pan Y
    J Am Acad Dermatol; 2018 Oct; 79(4):645-651.e4. PubMed ID: 30241625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.